Objective Over 10M Europeans suffer from neurodegenerative diseases such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Whilst there are many drugs that treat symptoms of these diseases, there are no therapies that can reverse or cure them.Our novel compound NeuroProtect has the potential to be a game changer by healing damaged neurons. NeuroProtect is a natural herb-derived compound with remarkable neuroprotective, neuro-rescuing, anti-apoptotic, and axon-outgrowth effects in mouse primary neuronal and human neuronal models. We have proven the compound’s efficiency in preliminary in-vitro tests. To take NeuroProtect to market fastest, we will focus on ALS that where we can use the orphan drug route and get clinical approval faster. This gives us an immediate target market of €300M per year in Europe, the US, Japan and Switzerland alone. Although ALS is relatively rare, the socioeconomic significance of the disease is extensive: a recent study showed that total lifetime costs for ALS were €1.15M per patient. NeuroProtect can therefore contribute to reduce the global economic burden of ALS. We are planning to take the standard route for commercialization in pharma industry: take the compound through pre-clinical studies, Phase I and Phase II clinical trials and then outlicense to a large pharma company who will refund our cost until they finish the Phase III trials and then pay us royalties. Our team is led by two experienced co-founders: Dr. Yuhong Dong, who has worked for a multinational pharmaceutical company for over 10 years as well as a physician for 4 years, and David Guan, who has over 10 years of management positions at multinational companies (HP, Honeywell). We are also supported by experienced advisors and investors to help us succeed.We are planning to use the Phase 1 funding to select our pre-clinical study partners, perform a market assessment, assess our IP strategy and update our business plan. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesbasic medicineneurologydementiaalzheimersocial scienceseconomics and businessbusiness and managementbusiness modelsmedical and health sciencesbasic medicineneurologyparkinsonmedical and health sciencesbasic medicineneurologyamyotrophic lateral sclerosis Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator SUNREGEN HEALTHCARE AG Net EU contribution € 50 000,00 Address ROBINIENWEG 51 4153 Reinach Switzerland See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Landschaft Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
